How to Build CHD@ZJU

CHD related Articles were retrieved from Pubmed, by entering keywords "coronary heart disease" and constrict the publish date from 2000/1/1 to now (2013/1/23). As a result, totally 115898 articles were found and their abstracts were downloaded for text mining. Since some articles didn't contain abstracts, only 88396 abstracts remained.

The text-mining process to get CHD related genes could be divided in to 5 following steps:

  • 1) Extracting all keywords from abstracts and ignoring those keywords start with numbers. 101402 keywords were extracted.

  • 2) Input these keywords into Gene library in ArrayTrack and find possible related genes. 4674 genes were then found.

  • 3) Put these 4674 genes again into pubmed abstracts to find related aticles. Only genes which offical name or there keyword description (such as prolactin for gene PRL) could be found in the abstract would be remained. As a result, 1247 genes were remained.

  • 4) Manually examined on the 1247 genes to validate it was acutally related to CHD. Some genes would be filtered if it represents other meanings (such as gene CAD, Entrez ID:790, carbamoyl-phosphate synthetase 2, is mostly meant coronary arterial disease in articles). 681 genes were then validated with at least one reference.

  • 5) All genes was compared with 1078 CHD genes in RGD database, and 370 genes were overlapped. These 370 genes were labels as "RGD_Supported" and the other 293 genes were labels as "REFERED". All 663 genes had supported references in CHD@ZJU which were examined by step 4.
  • How To contact Us

    Collaboration Information: Prof. Xiaohui Fan (fanxh@zju.edu.cn)

    Website using assistance : Leihong Wu (11019004@zju.edu.cn)



    Basic Information

    Gene Name: CACNB2

    Description: "calcium channel, voltage-dependent, beta 2 subunit"

    Entrez Gene ID: 783

    SwissProt Acc Number: Q08289

    RefSeq: NM_000724

    It was supported literatures to be a novel CHD related gene:

    ..Single-nucleotide polymorphisms (SNPs) within the regulatory 2 subunit of the voltage-gated calcium channel (CACNB2) may contribute to variable treatment response to antihypertensive drugs and adverse cardiovascular outcomes...

    From PMID: 21156931, in Journal Circ Cardiovasc Genet. , 2010


    References

    There were 1 potential papers with CACNB2 and CHD.

    PMIDTitleJournalsDetails
    21156931 Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).Circulation. Cardiovascular geneticsMore Details

    NOTEs: These result is mostly from TEXT-MINING and there might have mismatches.



    PPI interactions

    There were totally 2 unique genes interacted with CACNB2. Show PPI network

    Gene nameInteraction typereference PMIDCHD relation
    PRKACA in vitro10441130,10567342 CHD related
    REM1 in vivo14623965 No


    Involved FDA drugs

    StatusDrubBank IDNameIndicationATC Code
    approvedDB00270IsradipineFor the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics.C08CA03
    approvedDB00381AmlodipineFor the treatment of hypertension and chronic stable angina.C08CA01
    approvedDB00393NimodipineFor use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.C08CA06
    approvedDB00401NisoldipineFor the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.C08CA07
    approvedDB00622NicardipineUsed for the management of patients with chronic stable angina and for the treatment of hypertension.C08CA04
    approvedDB00653Magnesium Sulfate"Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant."A06AD04;A12CC02;B05XA05;D11AX05;V04CC02
    approvedDB00661Verapamil"For the treatment of hypertension, angina, and cluster headache prophylaxis."C08DA01
    approvedDB01023FelodipineFor the treatment of mild to moderate essential hypertension. C08CA02
    approvedDB01054NitrendipineFor the treatment of mild to moderate hypertensionC08CA08
    approvedDB01115Nifedipine"For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents). "C08CA05
    withdrawnDB01388MibefradilFor the treatment of angina and high blood pressure.C08CX01
    approvedDB06712Nilvadipine"For the management of vasospastic angina, chronic stable angina and hypertension."C08CA10